Oct 2026
Complement Activation Within Minutes Following Systemic Administration of AAV in the Presence of AAV Immunity.
A challenge of adeno-associated virus (AAV)-mediated gene therapy is the high prevalence of preexisting anticapsid antibodies, which can reduce vector efficacy and, after high-dose systemic administration, promote formation of antibody-vector complexes that activate complement. Complement-mediated toxicities reported a...
A. Caragiulo, J. Rosenberg, B. De et al.
· Human Gene Therapy · 0 citations